Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-31

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Comparison between the 4 groups of metabolic phenotypes of obesity as regard the presence and frequency of DKD
2. Relation between DKD , obesity (BMI) and metabolic risk factors in patients with type 2 DM

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy

NCT03865914

Diabetic Kidney Disease

RECRUITING

Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients

NCT05602532

Diabetes Mellitus, Type 2

UNKNOWN

Evaluation of Innovated Screening Tools for Type 2 Diabetes Among Chinese Population(SENSIBLE STUDY I)

NCT03025919

Type II Diabetes Mellitus

UNKNOWN

Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease

NCT06833541

Diabetic Nephropathy Type 2 Type 2 Diabetes Mellitus (T2DM) Chronic Kidney Disease

RECRUITING

Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

NCT05888909

Diabetic Nephropathy Type 2 Diabetic Kidney Disease Type 2 Diabetes

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes is the major cause of chronic kidney disease in industrialized countries. Individuals with diabetes and CKD are at a higher risk of developing End Stage Renal Disease and experiencing cardiovascular death. Type 2 DM complications are predicted by low estimated glomerular filtration rate and high urine albumin excretion(1).

Diabetic kidney disease is the primary cause of kidney failure globally, affecting 25% to 40% of persons with diabetes mellitus . Early diagnosis of high-risk patients is crucial due to the high-risk of progressive deterioration of kidney function leading to end-stage kidney disease, which ultimately requires kidney replacement therapy (2).

DKD risk factors include non modifiable factors like age , gender , race , genetics and modifiable factors like obesity and lifestyle. Obesity is typically associated with metabolic diseases such as hyperglycemia, dyslipidemia, and high blood pressure. Obesity's impact on renal insufficiency is debated ,and may be influenced by other metabolic abnormalities(3).

Metabolic phenotypes of obesity based on the BMI-based categories (non-obesity, obesity) and metabolic status (metabolically healthy status or metabolically unhealthy status): metabolically Healthy non-obesity (MHNO), metabolically healthy obesity (MHO), metabolically unhealthy non-obesity (MUNO) and metabolically unhealthy obesity (MUO)(3).

There is a strong correlation between obesity and the onset and course of chronic kidney disease, according to a number of population-based studies. the investigators think there are still unsolved issues about the connection between obesity and CKD(4).

so the study is concerned about detection of the relation between metabolic phenotypes of obesity and Diabetic kidney disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Kidney Disease Obesity Metabolic Syndrome Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

metabolically healthy non obesity (MHNO)

According to the NCEP ATP III definition, metabolic syndrome is present if three or more of the following five criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and fasting blood sugar over 100 mg/dl.

Obesity was defined as a BMI of ≥ 25.0 kg/m2 . Patients with a BMI of 18.5-\<23.0 were considered normal weight; for those with a BMI of 23.0-\<25.0 were overweight. The patients with normal weight and those who were overweight were collapsed into the non-obesity group.

so this group of patients are metabolically healthy and non obese with BMI 18.5 - \<25